Loading...

Novo Nordisk A/S

NONOFPNK
Healthcare
Biotechnology
$66.81
$2.24(3.46%)

Novo Nordisk A/S NONOF Peers

See (NONOF) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NONOF$66.81+3.46%283.6B17.27$3.70+2.56%
CSLLY$86.83+3.59%162.3B30.69$2.73+1.58%
CMXHF$173.54+7.31%77.5B29.30$5.46+1.73%
UCBJY$101.39+0.09%38.5B31.41$3.22+0.78%
UCBJF$202.16-0.83%37.7B30.67$6.46+1.54%
ARGNF$547.60+0.00%33.4B33.43$16.37N/A
ODTC$22,005.00+29.44%24.1B1.07$20,580.00N/A
IVBXF$11.35-0.70%19.8B-1200.00-$0.01N/A
SBMFF$0.88-4.35%15.7B87.63$0.01+1.02%
WXXWY$7.22-1.10%14.8B32.36$0.22N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NONOF vs CSLLY Comparison

NONOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NONOF stands at 283.6B. In comparison, CSLLY has a market cap of 162.3B. Regarding current trading prices, NONOF is priced at $66.81, while CSLLY trades at $86.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NONOF currently has a P/E ratio of 17.27, whereas CSLLY's P/E ratio is 30.69. In terms of profitability, NONOF's ROE is +0.81%, compared to CSLLY's ROE of +0.26%. Regarding short-term risk, NONOF is more volatile compared to CSLLY. This indicates potentially higher risk in terms of short-term price fluctuations for NONOF.

Stock Price Comparison

Loading...

Frequently Asked Questions

;